Trials / Completed
CompletedNCT00848640
Study of Sorafenib in Patients With Advanced Renal Cell Carcinoma
Multi-center,Middle East, Phase-II Study, Non-comparative, of the RAF-Kinase Inhibitor Sorafenib in Patients With Advanced Renal Cell Carcinoma to Evaluate The Efficacy and Tolerability of the Drug
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- Egyptian Foundation For Cancer Research · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose study is to evaluate the efficacy and safety of Sorafenib as first line treatment for patients - unsuitable for another approved first line therapy - with advanced RCC in the Middle East Region.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib | 400 mg twice daily |
Timeline
- Start date
- 2008-10-01
- Primary completion
- 2009-12-01
- Completion
- 2010-03-01
- First posted
- 2009-02-20
- Last updated
- 2010-05-26
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT00848640. Inclusion in this directory is not an endorsement.